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 Research suggests that specific compositions of gut microbiota can 
directly affect energy harvesting and fat storage, which may indicate a potential 
role of intestinal bacteria in the regulation of body weight (i.e., obesity). The 
purpose of the current study was to determine if prebiotic- and probiotic-based 
diets modify gut microbiota in genetically obese rodents. For this, female Zucker 
diabetic fatty (ZDF) rats were assigned diets containing fructooligosaccharides 
(FOS), Bifidobacterium (BIF), or Lactobacillus (LAC) for three weeks. qPCR was 
then used to measure levels of colonic Bifidobacterium, Lactobacillus, and total 
bacteria. At termination, there was no significant difference in Lactobacillus levels 
between diets. However, there was significantly less Bifidobacterium in BIF vs. 
FOS or LAC-fed rats. The evidence in this study shows there were no significant 
differences in Lactobacillus levels between any of the feeding groups and the 
control group, supporting the conclusion that ingestion of any of the tested 
supplemented food does not statistically modulate Lactobacillus numbers in 
female ZDF rats. However, the rats from the Bifidobacterium and FOS feeding 
groups had significantly higher colonic Bifidobacterium levels than the control 
group from ingesting the supplemented food, indicating that the presence of the 
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probiotic Bifidobacterium animalis subspecies lactis and the prebiotic FOS 
stimulated the growth of Bifidobacterium. 
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CHAPTER 1 
INTRODUCTION 
 
 
 Obesity and Type 2 diabetes mellitus (T2DM) are at epidemic 
proportions, with obesity rates increasing markedly over the past three decades. 
According to the Centers for Disease Control Behavioral Risk Factor Surveillance 
System, there was no state with obesity prevalence ≥15% in 1990. However, in 
just over 20 years this rate increased to ≥30% in several states.1  
Obesity results from an imbalance in energy intake and expenditure. 
Furthermore, obesity is linked to a variety of comorbidities, such as T2DM. 
Currently, >8% of Americans are diagnosed with T2DM, whereas an additional 
27% are thought to be undiagnosed.2 It is also estimated that approximately one 
in 400 people under 20 years of age in the U.S. have diabetes (type 1 or type 2).2 
The underlying factor contributing to increasing prevalence of T2DM is the 
corresponding rise in obesity rates.  
Probiotics are classified as live nonpathogenic microorganisms, such as 
bacteria or yeast, which confer physiological health benefits through changes in 
the host gut microbiota.3-5 Alternatively, prebiotics are selectively fermented 
ingredients (i.e., dietary fiber) that allow specific changes in the composition 
and/or activity of gut microbiota that also results in multiple health benefits for the 
host.6 However, not all dietary fibers are be considered prebiotic, as some 
stimulate potentially harmful bacterial growth or metabolism, and thus are not 
selective to beneficial bacteria.7 A plethora of research has investigated the 
positive effects of prebiotics and probiotics in humans. However, more recent 
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data has indicated that changes in gut microbiota through consumption of 
probiotics and prebiotics may influence the progression of obesity and its related 
comorbidities through modifications to energy harvesting and fat storage in 
hosts.8-11 
Statement of the problem. Preliminary research investigated the 
potential metabolic effects of prebiotic and probiotic based diets on genetically 
obese Zucker diabetic fatty (ZDF) rats.12 However, this previous work did not 
measure the bacteria profiles in obese and diabetic rats.  
Purposes of the study. The primary purpose of this study was to 
determine how consumption of prebiotics and probiotics modified gut microbiota 
in obese ZDF rats. Additionally, another purpose was to describe the bacterial 
profile in these animals associated with metabolic outcomes (i.e., hyperglycemia, 
adiposity, etc.). 
 Research questions. 1. Can we detect if probiotics or prebiotics made a 
significant difference in the number of microorganisms in the gut? 2. And, within 
those differences can we determine if we are selecting for either of the two 
genera we were measuring using q-PCR? 
Statement of hypothesis. We hypothesized that the prebiotics and 
probiotics would increase intestinal microflora and that we would select for both 
genera. We also hypothesized that the bacterial changes would correlate with 
positive metabolic outcomes. 
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CHAPTER 2 
REVIEW OF THE LITERATURE  
 
 
Obesity and T2DM are at epidemic proportions, with prevalence of each 
exhibiting a marked increase over the past three decades. Among the states that 
participated in the Centers for Disease Control Behavioral Risk Factor 
Surveillance System in 1990, 10 had prevalence of obesity less than 10% and no 
state had prevalence ≥15%. By 2000, no state had prevalence of obesity less 
than 10%, 23 states had a prevalence of 20–24%, and no state had a prevalence 
of ≥25%. However by 2010, no state had an obesity prevalence of less than 20% 
and 36 states had ≥25% with 12 of those having ≥30% prevalence (Figure 1). In 
2012, no state had a prevalence of obesity less than 20%, nine states and the 
District of Columbia had a prevalence of between 20–24%, and 13 states had a 
prevalence ≥30%.1 Obesity increases the risk of many health conditions, 
including coronary heart disease, stroke, hypertension, and cancers (i.e., 
endometrial, breast, and colon).13 
 Obesity results from increased intakes of energy-dense foods and 
decreased physical activity. However, when an entire population is exposed to 
the same nutritional stresses, certain individuals within that population do not 
experience similar weight gain and metabolic dysfunction. This suggests that 
there are additional mechanisms beyond energy intake and expenditure.8  
 Type 2 diabetes mellitus (T2DM) results in the body’s inefficient use of 
insulin. In 2011, T2DM affected over eight percent of Americans with an 
additional 27% still undiagnosed.14 About 3,600 people under 20 years of age in 
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the U.S. are newly diagnosed with T2DM every year.14 T2DM is largely caused 
from excess body weight and a lack of physical activity.15 
Much research has been conducted over the years regarding the effects 
of prebiotics and probiotics in the diet. More recently, research has demonstrated 
that specific compositions of gut microbiota can directly affect energy harvesting 
and fat storage. These data indicate that prebiotics/probiotics may distinctly 
impact pathophysiology of obesity.8-11 
Introduction to probiotics 
A diverse and complex gut microbial ecosystem exists that is 
indispensable for the human host’s health and wellbeing, even beyond the 
gastrointestinal tract. This environment is sterile in infancy, develops through 
childhood, matures in adulthood, and becomes more complex in old age. It is 
stable, but ever changing. Consequently, the “normal flora” is able to perform 
mechanistic roles that the human body cannot do itself.16  
Modern definitions. The World Health Organization (WHO) defines 
probiotics as live microorganisms which when administered in adequate amounts 
confer a health benefit on the host.3 Another source affirms a probiotic to be a 
live microorganism that is administered to alter the intestinal microflora, thereby 
conferring a beneficial effect on the patient’s health.4 And another more recently 
states that probiotics are viable, nonpathogenic microorganisms (bacteria or 
yeast) that are able to reach the intestines in sufficient numbers to confer benefit 
to the host.17 An integrated definition of probiotics is live, nonpathogenic 
microorganisms (bacteria or yeast) which when administered in adequate 
` 
 5 
amounts and which reach the intestines in sufficient numbers confer a beneficial 
effect on the health of the host.  
Microbial ecology of the GI tract 
Each person has a unique and stable gut microbial environment, but 
community shifts do occur. Age, gender, diet, health, and medications 
(antibiotics, in particular) can cause variations in the general blueprint associated 
with the human GI tract.18 About 3.3 million genes constitute the gut microbiome, 
about 150 times larger than the number of genes identified in the entire human 
genome. It is believed that up to 100 trillion microorganisms consisting of over 
1000 species inhabit the individual adult intestine at any given time,18,19 which is 
10X the number of cells in the human body.16 More recently, a study based on 
over 50,000 16S rRNA gene sequences distinguished about 1800 genera, 
16,000 species, and over 36,000 strains of bacteria overall in the human 
intestine.10 
Four bacterial groups comprise 98% of the total human gut microbiome: 
Actinobacteria (3%), Proteobacteria (8%), Bacteroidetes (23%), and Firmicutes 
(64%).10 The latter group constitutes the largest percentage and contains within it 
two genera of interest to this research, Bifidobacterium and lactic acid bacteria of 
the genus Lactobacillus. They are considered “normal flora” of the 
gastrointestinal tract.  
The acidic pH of the stomach prevents growth of most bacterial species. 
Only about 103 g-1 of intestinal contents survive this harsh environment and those 
that do are found predominantly on the walls of the stomach.20,21 These are 
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primarily Gram-positive facultatively anaerobic genera such as Lactobacillus,21 
though a few aerobic and Gram-negative bacteria can be found as well (Figure 
2).  
Bacterial concentration in the small intestine is typically between 104 and 
108 g-1 contents and primarily consists of some facultative anaerobes and some 
strict anaerobes. The number of commensal bacteria in the small intestine is still 
limited by the low pH from stomach acid.17 The pH of the duodenum is 6–6.5, but 
the area in and around the brush border can reach 7–8.22 In the proximal small 
intestine (i.e., duodenum and jejunum) Lactobacillus and Enterococcus 
predominate with bacterial concentration ranges from 104 and 105 g-1.10,20 In the 
distal small intestine (i.e., ileum), the bacterial composition begins to resemble 
the large intestine, which includes the following genera: Bacteroides, Clostridium, 
Eubacterium, Peptostreptococcus, Ruminococcus, Fusobacterium, Butyrovibrio, 
Enterobacterium, Lactobacillus, and Bifidobacterium.4 However relatively 
speaking, numbers of Lactobacillus drop 20 and gram-negative bacteria far 
outnumber gram-positive bacteria in the distal small intestine.4 The pH in the 
jejunum and ileum is about 7.5.22 
 The microflora of the colon is one of the most densely populated microbial 
habitats known, around 1011 to 1012 g-1 contents 4,17,18,23 and is quite diverse 
consisting of at least 500 microbial species.17 Bacteria make up about 60% of the 
mass of human fecal matter,17 dominated by the genera Bacteroides, 
Eubacterium, Fusobacterium, Butyrovibrio, Peptostretococcus, Clostridium, 
Fusobacterium, Ruminococcus, Lactobacillus, and Bifidobacterium.4,24 The large 
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intestine contains much larger numbers of obligate anaerobes than facultative 
anaerobes.25  
Species of the genera Eubacterium, Lactobacillus, and Bifidobacterium 
are typically used as probiotics in many dietary supplements and functional foods 
on the market today.18,26 These probiotics function to out-compete pathogenic 
bacteria such as Staphylococcus, Clostridium, and Pseudomonas. Two of these 
probiotic bacteria, Lactobacillus and Bifidobacterium, are the most commonly 
studied probiotic genera in the literature, selected based on their consistently 
viable, safe, and metabolically active characteristics. 
Health benefits of probiotic use 
Modern humans are considerably less exposed to microbes than our 
ancient ancestors with the modern Western diet consisting of much less fiber, 
non-digestible carbohydrates, and whole plant foods (fruits, vegetables, whole 
grains) and much more protein, saturated fat, and refined sugar. Such health 
issues as allergic and inflammatory maladies, metabolic syndrome (including 
obesity, hypertension, dyslipidemia, glucose intolerance, and insulin resistance), 
cancer, diabetes, stroke, and cardiovascular disease 27-29 are prevalent in 
modern Western society. Many studies have focused on beneficial health effects 
attributed to gut microbes’ symbiotic influence.  
Improvement of bowel function. A notable benefit is the improvement of 
bowel habits. Irritable bowel syndrome (IBS),28,30 diarrhea (particularly antibiotic-
associated),17,31 and ulcerative colitis 31,32 are among the most common gut 
problems studied with probiotic consumption. 
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Good bowel function relies heavily upon short-chain fatty acid (SCFA) 
formation. From the breakdown of unabsorbed carbohydrates, several species of 
Eubacterium and other Firmicutes produce the SCFA butyrate, a major source of 
nutrition for colonocytes.31,33 SCFAs have a positive effect on processes such as 
carcinogenesis and gene expression, energy metabolism, and cholesterol and 
lipid levels.29 Diets deficient in dietary fiber have decreased production/ 
concentration of fecal SCFAs34; however, it was observed that humans who 
consumed a restricted carbohydrate diet with probiotics maintained SCFA 
production.35 Furthermore, after the administration of probiotic supplements for 
six months, the microbiota associated with IBS patients changed toward that of 
IBS-free patients.30  
The symptoms of acute diarrhea have been improved with probiotics by 
21% and that of antibiotic-associated diarrhea improved by 52%.5 Lactobacillus 
have been particularly effective for improving the symptoms off chronic 
diarrhea.31 In eight of ten randomized controlled trials, it was reported that a 
significant number of participants experienced improvement from antibiotic-
associated diarrhea using the probiotic yeast Saccharomyces boulardii.36 Many 
GI disorders are treated with broad-spectrum antibiotics that actually exacerbate 
the disease with osmotic diarrhea and diarrhea associated with opportunistic 
and/or antibiotic resistant pathogenic bacteria, such as Clostridium difficile and C. 
perfringes, Salmonella, Staphylococcus aureus, or Proteus. As such, probiotic 
therapy can be used to quickly re-establish the normal flora and provide effective 
competition against pathogens.10,37-39 
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In patients with ulcerative colitis (UC), probiotics have been shown to 
relieve symptoms.31 Fecal samples from UC patients can contain very high 
concentrations of lactate.33 Some bacteria, including species of Eubacterium and 
Bifidobacterium, are able to ferment lactate to butyrate and this could explain 
how those without UC remove lactate from the colon.33 However, there are other 
colonic bacteria that also can produce butyrate, so the evidence for probiotics is 
still unclear in UC cases.  
Immune system benefits. The gut-associated lymphoid tissue (GALT) is a 
substantial component of the body’s immune system. Research has discovered 
that probiotics modulate the intestinal immune response18 and help to combat 
allergies.35,40 For example, Lactobacillus salivarius and other probiotics positively 
influence Natural Killer cells and monocytes. These leukocytes affect both the 
innate and specific immune responses.31,35  
Certain strains of Lactobacillus clearly play a role in the development and 
function of dendritic cells [special cells for presenting antigens to T helper cells 
(cells which signal immune responses)].41,42 The majority of dendritic cells in the 
GI tract are immature, and are subject to maturity based on their environment.41 
Mature dendritic cells produce the cytokine IL-12, which is important in 
differentiation of TH1 subset helper T cells.41,42  
Reduced intestinal permeability. The main entry points for most 
pathogenic bacteria are on luminal mucous membrane surfaces.20 Secretory 
Immunoglobulin A (sIgA) binds antigens on pathogens, entrapping them within a 
hydrophilic shell and preventing them from attaching to mucosal cells and 
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colonizing the colon.17,42 Probiotics have been shown to raise sIgA levels in the 
luminal mucous layer.17  
Once in the gastrointestinal tract, lactic acid bacteria produce bacteriocins, 
bacteriocidal (killing), or bacteriostatic (growth inhibiting) peptides.5,43 
Bacteriocins destroy gram-negative bacteria by penetrating the inner membrane 
or interrupting cell wall synthesis.5 Bacteriocins are promising as future 
antimicrobial agents because thus far there have been no side effects or 
resistance reported with their use.43 Additionally, due to the fact that they are 
proteins, which are easily degraded.43 
Probiotic bacteria such as Lactobacillus and Bifidobacterium produce 
SCFAs by fermenting 80–90% of the carbohydrates that the human host cannot 
digest (i.e., dietary fiber).18,31 The production of both SCFAs and high levels of 
lactic acid by lactic acid bacteria creates conditions detrimental to the pH-
sensitive cytoplasmic membrane of pathogenic bacteria (e.g., C. perfringens) and 
this causes the cells to lyse.10,20 SCFAs are beneficial to the host metabolism by 
increasing intestinal motility, absorption, defecation frequency, lipid and 
carbohydrate metabolism, mucus production, and blood flow to the large 
intestine.35,44,45 
Obesity link. A more recent hypothesis relates to the connection of obesity 
with the microbial composition of the gut. In mice, a mutation in the leptin (ob) 
gene causes deficiency of the adipose-regulating hormone leptin and is linked 
with early-onset obesity.46 The gut microbial community of genetically obese 
(ob/ob) mice contains 50% fewer Bacteroidetes species and 50% more 
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Firmicutes than their lean wild-type (+/+) littermates.9,11 Furthermore, the 
intestinal microbiota of obese mice is less diversified and contained a greater 
number of methanogens (Archaea that produce methane).10  
When feces of genetically obese mice was measured by bomb 
calorimetry, results disclosed substantially less energy than their wild-type 
siblings (Figure 3a).9 The proposed mechanism is that members of the 
Firmicutes convert more dietary fiber to short chain fatty acids, hence the host 
animal gets more fat from the same amount of food.10 Within two weeks, the 
germ-free mice experienced a significant increase in adiposity despite equal or 
decreased food quantity, indicating that obesity is transmissible (Figure 3b).9,11 
The conclusion is that the microbiota regulate the host’s harvest of energy and 
organic nutrients from the diet. 
In a study with human subjects, a similar Bacteroidetes/Firmicutes 
relationship was found regardless which diet the subjects were on (fat-restricted 
vs. carbohydrate-restricted). Interestingly, this correlation remained consistent 
following significant weight loss (Figure 4).11 Moreover, there was a significant 
correlation between the increase of Bacteroidetes and weight loss percentage 
(Figure 5).11   
As mentioned previously, methanogens are more abundant in the gut of 
ob/ob mice. Methanogens remove the products of fermentation from the gut, in 
particular, acetate, hydrogen (H2), and carbon dioxide (CO2). The removal of H2 
from the gut in the reduction of CO2 to methane makes the energetics of 
fermentation more favorable. This in turn, makes available additional nutrients for 
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the host to absorb, contributing to obesity.10 This has imminent therapeutic 
implications for the treatment of obesity.9  
More benefits of SCFAs. In addition to providing energy for colonocytes 
and lowering the pH of the colon to maintain the integrity of the mucosa, there 
are several other positive functions from the breakdown of nondigestible 
carbohydrates to SCFAs by probiotic bacteria. A summary of some of the 
benefits of probiotics, many well studied as well as others in earlier research 
stages, are listed in Table 1.  
Prebiotics 
 Prebiotics are nondigestible food ingredients that beneficially affect the 
host by selectively stimulating the growth and/or activity of one or a limited 
number of bacterial species already resident in the colon.7 This definition has 
more recently been updated to selectively fermented ingredients that allow 
specific changes. Both in the composition and/or activity in the gastrointestinal 
microbiota confer benefits upon host well-being and health.6 Consequently, not 
all dietary fibers can be considered prebiotic, as some dietary fibers stimulate 
potentially harmful bacterial growth and/or metabolism, and so are not selective 
to beneficial bacteria.7 
Humans lack the opacity to digest dietary fiber. As such, enteric microflora 
to catabolize them.47 When lactic acid bacteria (primarily Bifidobacterium) 
ferment fiber, the pH of the large intestine is reduced.20 Therefore, the growth of 
bacteria that are already resident in the colon can be accelerated with the use of 
prebiotics, which provides an advantage over simple probiotic usage.6,48  
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Interestingly, prebiotics possess differing fermentation profiles, so some 
metabolites can be converted or used as substrates for other prebiotics — this is 
called “metabolic cross-feeding”.49 Typically, the competition will positively affect 
those groups that are considered to be healthy for the host47 and negatively 
affect unfavorable bacteria.49-51 A prime example is by the anaerobic gut bacteria 
converting lactate produced by Bifidobacterium into butyrate and other SCFAs.48 
A requirement to be considered a prebiotic is that it must reach the colon 
as a fermentable substrate, meaning it has to be at least partially unhydrolyzed 
and unabsorbed in the small intestine.50-52 Prebiotics do not replace the normal 
flora but spur growth of the lactic acid bacteria such as Bifidobacterium and 
Lactobacillus, or activate them metabolically, or both. Thus, the colonic microbial 
composition is shifted by prebiotic consumption.47,51 
Specific prebiotics. Dietary fiber such as cellulose, lactosucrose, 
polydextrose, indigestible dextrin, soy polysaccharide, rice bran, and chitosan 
can alter the microbiota.4 In this country, the fructans are the most common 
prebiotic additive used in food.28 This group includes oligosaccharides such as 
galactooligosaccharides, lactulose,18 and short-chain fructooligosaccharides 
(synonymous with oligofructose) found in garlic, artichokes, onions, bananas, 
tomato, leeks, and wheat.28 Additionally, they are manufactured from sucrose or 
extracted from chicory.28,52,53 Xylooligosaccharides, isomaltooligosaccharides, 
and soybean oligosaccharides have all been touted as having prebiotic qualities, 
however more research is needed to bump them from their classification of 
tentative prebiotics to established prebiotics.52 
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Synbiotics  
Synbiotics are probiotics in the form of live microorganisms and certain 
prebiotics available in the same product concurrently.18,44,50 Synbiotics increase 
the likelihood that the probiotics survive and thrive since a preferred substrate, 
the prebiotic, is easily accessible.51 
The different segments of the intestine have disparate substrate 
concentrations and pH levels. A study of several combinations of probiotics and 
prebiotics found an optimum combination with a strain of Lactobacillus 
acidophilus with mannitol, fructooligosaccharides, and inulin.44 A list of examples 
of common probiotics, prebiotics, and synbiotics can be found in Table 2. 
There are so many probiotic products on the market, it is difficult for 
consumers to know what to purchase. There are many varieties with regards to 
formulations, stability, and quality control, as well as the problem of matching the 
appropriate probiotic with the disease or condition experienced by the patient, 
much less when prebiotics are added to the mix (synbiotics). 
Recommended dosages of prebiotics vary depending on the type of 
prebiotics consumed. Differing ranges of dosages are the result of the variable 
fermentation characteristics of the prebiotics.28 Package labels with terms such 
as starch, corn starch, modified food starch, and maltodextrin are indicators of 
resistant fiber, but not all are resistant to digestion, so the savvy consumer still 
must consult the actual fiber content on the nutritional label.28  
Typical carbohydrates of the human diet consist of resistant starch, non-
starch polysaccharides, such as cellulose, hemicellulose, inulin, and pectin, non-
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absorbable sugars and sugar alcohols, and chitin and amino sugars — none of 
which are well fermented by Lactobacillus.20 They may instead rely on the 
hydrolytic activity of bacteria such as Bifidobacterium and Bacteroides for their 
carbohydrates.20 However, they can ferment prebiotic carbohydrates such as 
galactosaccharides, fructooligosaccharides, raffinose, stachyose, lactitol, and 
palatinose.54  
Preliminary studies  
 The original feeding study on which this thesis is based was conducted by 
Michele Martin under the direction of Dr. D. Allan Higginbotham with the purpose 
of determining anti-obesity and anti-diabetic effects of prebiotics and probiotics 
added to soy protein diets in the female Zucker diabetic fatty or ZDF-Leprfa/Crl 
(ZDF) rat model.12 The ZDF emanates from the inbreeding of hyperglycemic 
Zucker obese rats.  
Male ZDF rats have an fa gene mutation in which the leptin receptor 
protein does not interact with leptin (the cytokine product of the ob gene which 
increases energy expenditure and decreases food intake, thus lowering body 
weight).55,56 This results in constant messages of hunger being sent out by the 
hypothalamus, and continuous eating ensues.57  
When put on a regular (Purina 5008, 16.7% kcal fat) diet the obese female 
ZDF rats will gain weight but remain euglycemic and will not develop diabetes. 58 
Female ZDF rats were used in the preliminary study because when subjected to 
a high fat diet (27% fat was used in the preliminary feeding study), they develop 
Type 2 Diabetes Mellitus.12 
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The hypothesis was that the prebiotics and probiotics would affect 
intestinal microflora and maximize the anti-obesity and anti-diabetic effect of the 
soy protein. The research questions were whether FOS, B. animalis subsp. 
lactis, or L. acidophilus in a soy-based diet decrease body weight and fat gain, 
and improve glycemic control in a preclinical model of T2DM. These strains were 
chosen as they have been well studied for their biological action and potential 
applications for commercial probiotic supplements. 
A soy-based protein diet was chosen based on evidence that it could 
improve glycemic control.12 Intestinal microflora may modify undigested soy 
protein components (possibly the isoflavones), and could be a method to improve 
glycemic control and prevent weight gain. Soy isoflavones affect glucose and 
triglyceride metabolism, which in turn, affect insulin levels.12 Soy polysaccharides 
can improve glucose tolerance by reducing glucose and triacylglycerol 
concentrations.12  
A 60-day study using rabbits as their animal model found that daily 
ingestion of a probiotic (Enterococcus faecium and Lactobacillus helveticus) soy 
product resulted in significant increases in fecal Lactobacillus and 
Bifidobacterium species counts compared to the control group. The unfermented 
soy food did not increase those bacterial populations. The experimental group 
also was found to have a reduced risk of cardiovascular disease.59  
Many different animal models have been used to study probiotics, 
including human. Important data can be gleaned using tissues from an animal 
host that would not be accessible from human models. By using rats in this 
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experiment, the entire colon could be extracted in order to take into account 
intestinal adhesion across the epithelium common with some strains of probiotic 
bacteria. Other tissues were taken from these experimental rats for the 
preliminary study.12 Even if the dosages/specific organisms used are not 
realistic/appropriate for human comparisons, we can potentially obtain relevant 
results from animal experiments suitable for advancing our understanding of the 
use and activity of probiotics in humans.  
This study aimed to determine changes in Lactobacillus, Bifidobacterium, 
and total bacteria in the colon and feces of rats fed conventional, prebiotic, and 
probiotic soy-based diets using these obese diabetic rats. The research 
questions are: can we detect if probiotics or prebiotics made a significant 
difference in the number of microorganisms in the gut; and, within those 
differences, can we determine if we are selected for either of the two study 
genera using q-PCR? 
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CHAPTER 3 
MATERIALS AND METHODS 
 
 
 Animals and Diet. Twenty-four female obese Zucker Diabetic Fatty rats 
(ZDF-Leprfa/Crl; Charles River Laboratories, Raleigh) were block randomized by 
body weight to control or experimental diets (n=6) (Table 3). All diets were 
isocaloric and isonitrogenous with 50% of total kcal from fat. Experimental diets 
were supplemented with 2.5% of fructooligosaccharide (FOS), Bifidobacterium 
animalis (BIF), or Lactobacillus acidophilus (LAC). Animals were housed in the 
Southern Illinois University Carbondale Vivarium under the supervision of the 
Institutional Animal Care and Use Committee (IACUC). Rooms were temperature 
controlled and light regulated, and rats were housed in individual wire cages. 
Food was measured daily and rats were weighed three times per week.12  
All diets contained 27% fat. The control soy diet was comprised of 42.9% 
carbohydrate and 17.9% starch while the FOS, Bifidobacterium, and 
Lactobacillus soy diets all consisted of 40.4% carbohydrate, 25% sucrose, 15.4% 
starch, and 2.5% functional (see Table 3 for complete composition of 
experimental diets).  
 Sample Collection. The feeding study was conducted for three weeks 
until rats exhibited severe hypoglycemia with lesions. Rats were euthanized and 
tissue samples collected. A colon sample was also removed from each rat, 
placed in a sterile conical tube, and immediately immersed in liquid nitrogen until 
samples were placed in an ultra-cold (-80°C) freezer.  
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Bacterial acquisition, growth conditions, and isolation. Bacterial 
control strains were obtained from the SIUC Department of Microbiology’s stock 
culture collection and were grown under semi-aerobic conditions overnight in 
10 ml screw-capped tubes partially filled with Bacto Tryptic Soy (TS) broth at 
37°C. These strains were used as controls for primer optimization (Table 4). 
Two strains intended for use in this research, Lactobacillus acidophilus 
(NRRL B-4495) and Bifidobacterium animalis (NRRL B-41405) were obtained 
from the culture collection of Dr. Alejandro P. Rooney at the U.S. Department of 
Agriculture’s National Center for Agricultural Utilization Research in Peoria, 
Illinois. Due to problems growing a sterile B. animalis culture, B. infantis was later 
acquired from Chr. Hansen, Inc. (I-Powder-50; Milwaukee). The taxonomic 
descriptions of the genera Lactobacillus and Bifidobacterium are shown in 
Appendix A. 
Probiotic strains were grown aerobically overnight in MRS broth in partially 
filled 10 ml screw-capped tubes or on agar plates in BBL Gas-Pak™ jars (Becton 
Dickinson, Sparks, MD) at 37˚C. The MRS medium (containing trypticase soy 
powder, dextrose, beef brain heart infusion, peptone, sodium acetate, yeast 
extract, sodium citrate tribasic dihydrate, sodium phosphate dibasic anhydrous, 
polysorbate (Tween) 80, magnesium sulfate heptahydrate, manganese sulfate 
tetrahydrate, thiosulfate, L-cysteine hydrochloride, MOPS, and cobalamin) was 
adjusted to pH 6.5 ± 0.2 at room temperature, brought to volume, and gently 
heated to boiling. Medium was then added to loosely capped 10 ml screw-
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capped tubes and autoclaved at 121°C for 20 min. For culture plates, Bacto™ 
agar was added to the medium prior to the boiling step. 
Quantitative PCR. To optimize primers, relative quantification of bacterial 
DNA in samples was determined using quantitative real-time PCR (qPCR), which 
is 10–100 times more sensitive than the plate-count method.60 Pure cultures of 
all bacterial control and study strains were harvested from a centrifuged bacterial 
pellet from 10 ml of culture and subsequently isolated using the E.Z.N.A.™ 
Bacterial DNA Isolation Kit (D3350, Omega Bio-tek, Inc., Norcross, GE) 
according to manufacturer’s instructions.  
Comparison tests were performed to evaluate primers sets for optimum 
determination of relative Bifidobacterium, Lactobacillus, and total bacteria 
concentration in colon samples (Appendix B). The 16S gBifid, 16S Lact, and 16s 
p338fGC/P518R primer sets were used for measurement of Bifidobacterium, 
Lactobacillus, and total bacteria, respectively. All primer sets tested were 
purchased from Integrated DNA Technologies, Inc. (Coralville, IA) and are listed 
in Table 5. Primer specificity was confirmed by real-time qPCR with genomic 
DNA from overnight cultures. No cross-reactivity was found with any of the non-
target species tested.  
Quantification of Bifidobacterium, Lactobacillus, and total bacteria was 
achieved with real-time qPCR with ribosomal DNA-targeted genus-specific 
primers using the CFX96™ Real-Time PCR Detection System (Bio-Rad Life 
Science Research, Hercules, CA). Each plate experiment was replicated three 
times and each reaction was carried out in triplicate in a volume of 15 µL using 
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96-well optical-grade plates (MLL9601, Bio-Rad Life Science Research). Each 
plate contained three no-template controls. The qPCR reactions were designed 
as follows: 95ºC for 10 min (1X), 95ºC for 10 sec (40X), 57ºC for 30 sec (1X), 
72ºC for 30 sec (1X), and 95ºC for 10 sec (1X). The Ct values were averaged for 
each animal and primer set. Relative concentrations were calculated using the 2-
∆∆CT method.61 FastStart DNA Master SYBR Green (Roche, Indianapolis) was 
used for all qPCR reactions. 
Statistical Analysis. Data were analyzed with SPSS 20.0.0 (SPSS Inc., 
Chicago, IL) and tested for normal distribution using the Shapiro-Wilk test. Non-
parametric data were transformed and one-way analysis of variance (ANOVA) 
test was performed. If ANOVA data were significant (p<.05), post hoc 
comparisons were then made between individual groups using Tukey’s test. 
Mean differences were considered significant at p<.05. 
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CHAPTER 4 
RESULTS 
 
 This study was conducted to determine how the consumption of prebiotics 
and probiotics modified gut microbiota in obese ZDF rats and to describe the 
bacterial profile in these animals associated with metabolic outcomes (i.e., 
hyperglycemia, adiposity, etc.). The experiments were designed to detect if soy 
food supplemented with 2.5% fructooligosaccharides (FOS), Bifidobacterium 
animalis (BIF), or Lactobacillus acidophilus (LAC) made a significant difference in 
the number of microorganisms found in the gut; and, within those differences, if it 
could be determined that either Lactobacillus or Bifidobacterium were selected 
for. 
Lactobacillus levels in obese female ZDF rats. Following three weeks 
on experimental diets (Table 3), there were no significant differences in 
Lactobacillus levels detected between diet groups F = 0.087, p=0.97; Figure 6). 
To determine whether DNA levels of Lactobacillus (∆CT) were associated with 
reported metabolic outcomes in female ZDF rats (Appendix C), Pearson’s 
correlation coefficient (r) was used to assess the relationship with blood glucose 
(Figure 7A) and body weight (Figure 7B). There was no significant correlation 
observed between Lactobacillus levels and blood glucose (r=0.10, p=0.96) or 
body weight (r = -0.24, p = 0.27).  
Bifidobacterium levels in obese female ZDF rats. Unlike Lactobacillus, 
there was a significant difference in Bifidobacterium content at termination 
(F=9.46, p<0.001; Figure 8). More specifically, Bifidobacterium was lower in 
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female obese ZDF rats fed BIF compared to LAC or FOS (p<0.05) (Figure 8). 
There was also a significantly greater Bifidobacterium in FOS vs. CON fed rats 
(data not shown; p<0.05). Pearson’s correlation coefficient (r) was then used to 
determine if these differences in Bifidobacterium levels were associated with 
changes in blood glucose (Figure 9A) or body weight (Figure 9B). There was no 
significant correlation observed between Bifidobacterium levels and blood 
glucose (r=0.017, p=0.87) or body weight (r=-0.04, p=0.95).  
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CHAPTER 5 
DISCUSSION & CONCLUSIONS 
 
 
The purpose of this project was to quantitatively compare the probiotic and 
total gut bacteria levels of female Zucker diabetic fatty (ZDF) rats whose soy-
based diet was supplemented with prebiotic FOS, probiotic B. animalis, or 
probiotic L. acidophilus. The evidence in this study shows there were no 
significant differences in Lactobacillus levels between any of the feeding groups 
and the control group, supporting the conclusion that ingestion of any of the 
tested supplemented food does not statistically modulate Lactobacillus numbers 
in female ZDF rats. However, the rats from the Bifidobacterium and FOS feeding 
groups had significantly higher colonic Bifidobacterium levels than the control 
group from ingesting the supplemented food, indicating that the presence of the 
probiotic Bifidobacterium animalis subspecies lactis and the prebiotic FOS 
stimulated the growth of Bifidobacterium.  
FOS supplementation of 0.25% FOS significantly stimulated intestinal 
numbers of Lactobacillus over their control group and significantly lowered the 
populations of the harmful bacteria E. coli and C. perfringens in a study with 
broiler chickens.62 However, the 0.50% FOS feeding group gained less body 
weight, had less Lactobacillus measured in their intestines, and more E. coli and 
C. perfringens than the 0.25% FOS group, indicating that it was excessive to 
supplement at the 0.50% FOS level.62 This may hold some significance in that 
the preliminary study used 2.5% FOS supplement and the results of this study 
increased but showed no significance. 
` 
 25 
In most probiotic studies Lactobacillus counts are increased after probiotic 
consumption. However, one probiotic study involving elderly volunteers reported 
a decrease in the genus Lactobacillus bacteria in fecal counts after feeding a 
probiotic cocktail of various Lactobacillus and Bifidobacterium species.63 The 
researchers speculated the differences in results may have been caused by 
differing isolation and identification techniques used.63 Another study involving 
healthy, elderly volunteers yielded significantly higher numbers of bacteria from 
the genus Bifidobacterium during the two-week synbiotic (containing 
Bifidobacterium capsules and ingested oligofructose) feeding period and during 
the three-week post-feeding period.64 The relative levels of colonic 
Bifidobacterium of rats in the FOS feeding group differed from that of the control 
and Bifidobacterium feeding groups, probably reflecting the prebiotic effect of 
FOS, as it is known to stimulate Bifidobacterium numbers when administered as 
a dietary supplement.65 B. animalis was detected in the bowel of rats 
administered food supplemented with the prebiotic inulin compared to the control 
group in another study.66 And in another, the mean level of Bifidobacte4rium was 
between 2.2 and 3.5 times higher in short chain (sc)FOS-fed piglets than in 
control animals.53  
The results of this study are similar to the studies discussed above in that 
Lactobacillus counts did not alter significantly, but Bifidobacterium counts did 
increase significantly. They indicate that an interesting addition to our study 
would have been to add two synbiotic feeding groups, Bifidobacterium/FOS and 
Lactobacillus/FOS. Results from previous studies have shown that an easily 
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accessed, preferred substrate increases the viability of the probiotic.51 In order 
for all the rats to begin the experiment with a “sterile” gut, they could have been 
given a round of antibiotics beforehand. Also, although Lactobacillus wis not 
significantly higher in this study, it is trending higher. Therefore, it is possible that 
with a higher n, the result may have become significant. 
The hypothesis of the preliminary study was that the prebiotics or 
probiotics added to the soy protein could have some effect on the intestinal 
microflora. In the Bifidobacterium-fed group, lipid levels were higher than any of 
the other feeding groups. It was concluded that the higher concentration of 
probiotics likely produced SCFA and amino acids which were absorbed in the 
colon and subsequently increased body lipids.12 It is likely that the Firmicutes in 
the gut are responsible for this conversion.10  
Using male rats in the study would provide another statistical group. 
Further, use of a rat species that was not obese or prone to diabetes would likely 
have resulted in a longer, more complete study of the effects of the different diet 
groups since these rats developed diabetes so quickly and severely that the 
study had to be stopped. In addition, it is possible that the wire-floor cages could 
have been stressful for the animals as opposed to litter on a smooth cage floor, 
causing the rats to eat more than they normally would have. This could alter the 
ratios of the gut bacteria genera, thereby negatively skewing the results.62 
A stool kit was used in DNA recovery from the colon samples for this 
study. This method/kit may select for certain bacteria because not all bacteria 
lyse equally well.67 Gram positive bacteria cell walls can be harder to penetrate 
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than those of Gram negative bacteria.29,68 PCR reaction efficiencies may select 
for bacteria with lower GC ratios than say, Bifidobacterium, due to various 
melting and renaturation efficiencies.29 Even slight variations in DNA sequences 
can cause non-detection of certain bacteria.68 
Copy number variation is an application that requires accurate, absolute 
quantification. This now can be accomplished using a recently developed 
technology called droplet digital PCR that was not available at the time of data 
collection for this research. This technology allows only about one target 
molecule per reaction, and then hundreds or thousands of these reactions are 
run in parallel.69 These reactions are not quantitative, but can determine the 
proportion that contains template for the target in question, and precisely 
determine copy number in the original sample. 
Recommendations. There has been a vast amount of research done in 
the field of prebiotics and probiotics demonstrating health improvements, but 
there is a lack of cause and effect answers. Future research needs to link 
prebiotic and/or probiotic modifications with precise physiological actions leading 
to specific health benefits. The colonic measurements performed in this study 
cannot be indicative of prebiotic and probiotic feeding effects on the small 
intestinal ecosystem as a major target of viable probiotic strains. Furthermore, 
the small intestine is the most important site of energy absorption. Therefore, the 
results of this study cannot lead to any suppositions toward understanding the 
relationship between obesity and the microbiome. After recent discoveries of this 
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relationship, modern research likely will focus heavily on this aspect of prebiotic 
and probiotic supplementation. 
 Metagenomics approaches will provide valuable genetic information 
regarding gastrointestinal bacteria. For example, the recent Human Microbiome 
Project directed by the National Institutes of Health (NIH) is sequencing and 
analyzing the genomes of about 600 GI bacteria. This study will examine the 
roles of microbial communities in the gut as well as bacteria from other human 
body sites, how they all interact with each other, and the relationship between 
disease and changes in the human microbiome.70-72 This will give us a global 
view of the potential beneficial effects of probiotic and other commensal intestinal 
bacteria. 
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TABLES 
 
Table 1. Summary of some benefits of probiotics administration to 
humans 
 
Decrease incidence of dental caries 28 
Attenuate lactose intolerance symptoms 28 
Alleviates mucosal inflammation due to H. pylori infection 73 
Reduce intestinal pathogens: 
 reduce intestinal permeability by modifying epithelial barrier function 17 
inhibit the growth and survival of pathogenic bacteria 4,10,17,31 
 interrupt bound pathogenic bacteria 17 
promote defense barrier functions on the gut epithelial cells 74 
interrupt DNA, RNA, or protein synthesis/structure, or penetrate the inner 
membrane of gram-positive pathogens 17 
produce high levels of lactic acid and SCFAs to the detriment of pH-
sensitive pathogens 10,20 
increase intestinal motility, absorption, defecation frequency, lipid and 
carbohydrate metabolism, mucus production, and blood flow to the 
large intestine from production of SCFAs 35,44,45 
modify epithelial barrier function by reducing intestinal permeability 17 
Improve bowel function: 
produce digestive enzymes 51 
reduce symptoms of irritable bowel syndrome (IBS) 28,30 
shorten duration of infant infectious diarrhea 28 
reduce symptoms of diarrhea (particularly antibiotic-associated) 17,31 
reduce symptoms of ulcerative colitis 31,32 
provide energy for colonocytes 31,33 
lower the pH of the colon to maintain integrity of the mucosa 41,75 
Immune system benefits: 
increase intestinal immune response 18 
combat allergies 35,40,76 
improve atopic dermatitis in children 2 years and over 77 
affect development and function of dendritic cells 41 
raise sIgA secretion levels into the luminal mucous layer 17 
repress rotaviruses 51 
Reduce respiratory infections 28 
Prevent urinary tract and vaginal infections 78 
Treat infections during pregnancy 78 
Retard carcinogenesis process 44 
Lower hypertension 79 
Obesity link 9,11 
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Table 2. Examples of common probiotics, prebiotics, and synbiotics1 
Probiotics 
Lactobacillus 
L. acidophilus 
L. casei 
L. delbrueckii subsp. bulgaricus 
L. reuteri 
L. brevis 
L. cellobiosus 
L. curvatus 
L. fermentum 
L. plantarum 
Gram-positive cocci 
Lactococcus lactis subsp. cremoris 
Streptococcus salivarius subsp. thermophilus 
Enterococcus faecium 
Streptococcus diacetylactis 
Streptococcus intermedius 
Bifidobacterium 
B. bifidum 
B. adolescentis 
B. animalis 
B. infantis 
B. longum 
B. thermophilum 
Prebiotics 
 FOS (e.g., oligofructose and neosugar) 
 Inulin 
 GOS 
 Lactulose 
 Lactitol 
Synbiotics 
 Bifidobacterium + FOS 
 Lactobacillus + lactitol 
 Bifidobacterium + GOS 
   
1 Some still under evaluation.  
FOS, fructooligosaccharides; GOS, galactooligosaccharides. 51  
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Table 3. Composition of experimental diets1 
Ingredient2      CON    FOS3        BIF4      LAC5 
Soy6  200 200 200 200 
Sucrose  250 250 250 250 
Starch  179 154 154 154 
Functional      0   25   25   25 
Soybean oil    70   70   70   70 
Lard  200 200 200 200 
Fiber    50   50   50   50 
Vitamins    10   10   10   10 
Minerals    35   35   35   35 
Cysteine      3     3     3     3 
Choline      2.5     2.5     2.5     2.5 
BTHQ      0.014     0.014     0.014     0.014 
 
1Energy Density: 4.85 kcal/g-1 (Protein 17%, Carbohydrate 33%, and Fat 50% of 
total kcal) 
2ICN Biomedicals, Costa Mesa, CA 
3FOS diet contains 2.5% fructooligosaccharide 
4Bifidobacterium animalis subspecies lactis (1.0 x 1010 cfu g-1, Lyoferm, Inc., 
Indianapolis) 
5Lactobacillus acidophilus (1.0 x 109 cfu g-1, Lyoferm, Inc., Indianapolis) 
6Supro® Soy Protein Isolate, Solae LLC, St. Louis, MO
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Table 4. Bacterial strains used as controls during the primer 
optimization 
 
Bacteria Gram-stain 
Lactobacillus acidophilus + 
Bifidobacterium infantis + 
Bacillus cereus + 
Staphylococcus aureus + 
Enterococcus faecalis + 
Enterobacter aerogenes – 
Proteus vulgaris – 
Salmonella typhimurium – 
Escherichia coli – 
 
Table 5. qPCR primers tested for Bifidobacterium, Lactobacillus, and total bacteria concentration 
 
        Annealing   
Primer Target Genera/Group    Temp (ºC)        Sequence 5'→3' 
 
Lact-F  Lactobacillus (Leuconostoc,     52.8         CACCGCTACACATGGAG 
  Pediococcus, Aerococcus, &  
Lact-R Weissella, but not Enterococcus/      52.7         AGCAGTAGGGAATCTTCCA 
Streptococcus        
 
g-Bifid-F          53.7         GGTGTTCTTCCCGATATCTACA 
  Bifidobacterium 
g-Bifid-R          55.6         CTCCTGGAAACGGGTGG 
 
recA-F          57.8         CGTYTCBCAGCCGGAYAAC 
  Bifidobacterium 
recA-R          58.5         CCARVGCRCCGGTCATC 
 
 
P338FGC          61.3         ACTCCTACGGGAGGCAGCAG 
  Domain Bacteria 
P518R          58.7         ATTACCGCGGCTGCTGG 
 
8F           54.3         AGAGTTTGATCMTGGCTCAG 
  Domain Bacteria 
529R           65.1         ACCGCGGCKGCTGG
33
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FIGURES 
 
 
 
Figure 1. Obesity trends among U.S. adults. The CDC’s Behavioral Risk 
Factor Surveillance System reports indicate obesity trends according to BMI 
calculated from self-reported telephone interviews with U.S. adults in 1990, 2000, 
and 2010. Obesity is indicated by a BMI of ≥30 (e.g., about 30 lbs. overweight 
for 5’4” person) 1. In 1990, no state had a prevalence of obesity ≥15%. However, 
by 2012, several states had a prevalence ≥30%. 
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Figure 2. The gastrointestinal tract, illustrating bacterial quantities (each 
symbol ≈ 10-fold cells. Aerobic (red) vs. anaerobic (blue), and Gram-negative (–) 
vs. Gram positive (+).4,21 
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Figure 3. Microbiota transplantation. These experiments demonstrate that 
ob/ob microbiota harvest more dietary energy than their wild-type littermates. (a) 
Fecal gross energy content of lean (+/+, ob/+; n=9) vs. obese (ob/ob; n=13) 
C57BL/6J mice demonstrates that obese mice have significantly less energy that 
remains in their feces than lean wild-type mice. (b) Germ-free wild-type mice 
colonized with microbiota from the cecum of obese (ob/ob) donor mice displayed 
a significantly higher percentage increase in body fat percentage over wild-type 
mice colonized from lean (+/+) donors. Figure adapted Turnbaugh et al. (2006) 9.  
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Figure 4. Relative abundance of Firmicutes and Bacteroidetes. In a one-year 
human study, the relative abundance of Firmicutes and Bacteroidetes. Sample 
average values at each time point (n = 11 or 12/time point). Lean controls 
averaged one year apart. Figure adapted Ley et al. (2006)11. 
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Figure 5. Bacteroidetes relative change in abundance. The Bacteroidetes 
group increased in abundance according to percentage of body weight lost in a 
study of a carbohydrate-restricted diet group with subjects who experienced 
greater than 2% body weight loss and subjects from a fat-restricted diet group 
who lost greater than 6% body weight. Figure adapted Ley et al. (2006)11. 
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Figure 6. The abundance levels of Lactobacillus in DNA extracted from 
colon of female ZDF rats. Data values represent mean fold change calculated 
using the 2-ΔΔCT method61. Data were analyzed using ΔCt values for each sample 
(Ct Lactobacillus n – Ct Total Bacteria n), n = 24. The data were tested for 
normality (Kolmogorov-Smirnov, p=0.13 and Shapiro-Wilk, p=0.18) and analyzed 
using a one-way analysis of variance (ANOVA). There was no significant 
difference in abundance levels of Lactobacillus (F=0.087, p=0.97).  
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Figure 7. Relationship between Lactobacillus levels in colon and blood 
glucose and body weight in female ZDF rats. Scatter plot analysis of relative 
Lactobacillus levels (fold change) and (A) fasting blood glucose concentration 
(mg/dl), and (B) body weight (grams). Pearson’s correlation coefficients (r) were 
r=0.10 (p=0.96) and r=-0.24 (p=0.27) for glucose and body weight, respectively.  
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Figure 8. The abundance levels of Bifidobacterium in DNA extracted from 
colon of female ZDF rats. Data values represent mean fold change calculated 
using the 2-ΔΔCT method 61. Data were analyzed using ΔCT values for each sample 
(CT Bifidobacterium n – CT Total Bacteria n), n = 24. The data were tested for 
normality (Kolmogorov-Smirnov, p=0.13 and Shapiro-Wilk, p=0.18) and analyzed 
using a one-way analysis of variance (ANOVA). There was a significant 
difference in abundance levels of Bifidobacterium among groups (F= 9.46, 
p<0.001). Multiple comparisons were then made using Tukey’s HSD test. 
Significant differences (at p<0.05) between means were indicated by different 
letters. 
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Figure 9. Relationship between Bifidobacterium levels in colon and blood 
glucose and body weight in female ZDF rats. Scatter plots analysis of relative 
Bifidobacterium levels (fold change) and (A) fasting blood glucose concentration 
(mg/dl), and (B) body weight (grams). Pearson’s correlation coefficients were 
0.017 (p=0.87) and -0.04 (p=0.95) for glucose and body weight, respectively.   
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APPENDIX A 
Taxonomic Description of Genera Lactobacillus and Bifidobacterium 
 
 
 
 
 
BACTERIA 
Firmicutes Actinobacteria 
Bacilli 
 
Lactobacillales 
Lactobacillacea
e 
Lactobacillus 
Actinobacteria 
Bifidobacteriumles 
Bifidobacteriumceae 
Bifidobacterium 
Actinobacteridae 
 
s 
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APPENDIX B 
 
qPCR primer tests for Bifidobacterium, Lactobacillus, and total 
bacteria 
 
 
Bifidobacterium. Graphical representation of real-time qPCR results comparing 
primer sets to detect genus Bifidobacterium, tested by using DNA of control 
bacteria, Lactobacillus infantis, and Bifidobacterium animalis subspecies lactis. 
 
 
Lactobacillus. Graphical representation of real-time qPCR results for the primer 
set Lact to detect genus Lactobacillus, tested using DNA of control bacteria, 
Lactobacillus infantis, and Bifidobacterium animalis subspecies lactis. 
 
 
Total Bacteria. Graphical representation of real-time qPCR results comparing 
primer sets to detect total bacteria.
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APPENDIX C 
 
Measurements of ZDF rats subjected to high-fat diets containing prebiotics  
and probiotic for three weeks 
 
  CON FOS BIF LAC 
   Total food 
   intake (g) 391.7±8.4   410.9±8.7  394.8±10.0 
   
402.1±14.1 
 
   Final blood 
   glucose (mg/dl) 270.0±34.6  
    
241.2±44.1  306.0±35.9    320.0±9.5 
 
   Body weight 
   gain (g) 118.2±4.0  114.8±6.1   113.7±4.6    114.8±3.7 
 
   Final body 
   lipid (%) 
 
48.2±2.7  
 
 45.9±1.9  
 
 59.5±3.1  
 
  46.1±3.7 
 
Data represent treatment means ± standard error. Letters indicate significant difference 
between groups as determined from one-way ANOVA and Tukey HSD multiple 
comparison. 
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